Claims for Patent: 8,415,133

Summary for Patent: 8,415,133

Title:	Process for producing poxviruses and poxvirus compositions
Abstract:	The present invention relates to compositions and pharmaceutical compositions comprising poxviruses and more particularly extracellular enveloped viruses. The present invention also relates to a process for producing poxviruses and poxviruses obtained thereof. Moreover, the present invention also relates to the use of said poxvirus and said composition for the preparation of a medicament.
Inventor(s):	Malarme; Daniel (Oberhaslach, FR), Cordier; Yves (Strasbourg, FR), Sene; Claude (Strasbourg, FR)
Assignee:	Transgene S.A. (Illkirch, FR)
Application Number:	13/279,525
Patent Claims:	1. A process for producing a composition of a wild type, an attenuated, and/or a recombinant poxvirus with no targeted infection specificity comprising the steps of: a) preparing a cell culture of packaging cells, b) infecting said cell culture to obtain infected cells, c) culturing said infected cells for an appropriate period of time to produce poxviral particles, d) recovering said poxviral particles from the culture supernatant and from packaging cells disrupted by high speed homogenizer, to obtain a poxviral particle mixture, e) clarifying said poxviral particle mixture, thereby removing cellular debris, wherein said clarifying comprises depth filtration, to obtain a clarified poxviral particle mixture, f) concentrating said clarified poxviral particle mixture, wherein said concentrating comprises microfiltration, to obtain a concentrated poxviral particle mixture, and g) diafiltrating said concentrated poxviral mixture, wherein said process is free from animal products and does not use nuclease, wherein said poxvirus composition comprises intracellular mature virus ("IMV") and extracellular enveloped virus ("EEV") with more than 1% EEV, and wherein said packaging cells are chicken embryo fibroblast ("CEF") prepared by enzymatic digestion. 2. The process of claim 1, wherein said poxvirus composition comprises more than 5% EEV. 3. The process of claim 1 or claim 2, wherein said process for producing said poxvirus composition further comprises step h) of tangential filtration. 4. The process of claim 1, wherein said packaging cell is chicken embryo fibroblast ("CEF") prepared by digestion of embryos tissue with trypsin and dispase. 5. The process of claim 1, wherein said poxvirus is an orthopoxvirus. 6. The process of claim 5, wherein said orthopoxvirus is a Vaccinia virus. 7. The process of claim 6, wherein said Vaccinia virus is Modified Vaccinia Virus Ankara (MVA). 8. The process of claim 7, wherein said MVA is selected from MAV575 (ECACC V00120707) and MVA-BN (ECACC V00083008). 9. The process of claim 1, wherein microfiltration and/or dialfiltration step is/are performed on filtration membranes having a pore size of between 00.1 .mu.m and 0.15 .mu.m. 10. The process of claim 9, wherein said filtration membranes have a pore size of 0.1 .mu.m. 11. The process of claim 1, wherein said enzymatic digestion is performed using trypsin, collagenase, pronase, dispase, hyaluronidase, neuraminidase, or a combination thereof.

Details for Patent 8,415,133

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	05/05/2004		2026-06-20
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	12/02/2004		2026-06-20
Amphastar Pharmaceuticals, Inc.	AMPHADASE	hyaluronidase	Injection	021665	10/26/2004		2026-06-20
Akorn, Inc.	HYDASE	hyaluronidase	Injection	021716	10/25/2005		2026-06-20
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2026-06-20